Document is current
Any future updates will be listed below
-
Authors
Liu, Chen https://orcid.org/0000-0002-1868-8347
Ji, Yongpeng
Wu, Xiaoyan
Cerqueira, Brenda
Cade, David
Du, Peng
Yang, Zhi
-
Funding
Funding for this research was provided by:
Telix Pharmaceuticals (Telix Pharmaceuticals)
- License Information
-
More Information
Article History
Received: 12 June 2025
Accepted: 16 October 2025
First Online: 24 December 2025
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki, China Good Clinical Practice (GCP; 2020 version; GCP registration number of Beijing Cancer Hospital: 2019000050), and the International Conference on Harmonisation E6 guidance for GCP. The study was approved by the Ethics Committee of Beijing Cancer Hospital (2022YW225) prior to initiation. All patients provided written informed consent prior to participation in the study. No study-related procedure was implemented before signed written informed consent forms were obtained from patients or their legally authorized representative(s).
: Not required.
: This study was sponsored by Telix Pharmaceuticals, with Grand Pharmaceutical (China) as local sponsor. BC and DC are employees of Telix Pharmaceuticals.
